• Mutation; HGNC; 6515; LATS2; Simple; c.2652_2665+111del125; Zygosity=Unspecified (PubMed=21245096).
  

PubMed=19380521; DOI=10.1093/carcin/bgp097
Kawaguchi K., Murakami H., Taniguchi T., Fujii M., Kawata S., Fukui T., Kondo Y., Osada H., Usami N., Yokoi K., Ueda Y., Yatabe Y., Ito M., Horio Y., Hida T., Sekido Y.
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Carcinogenesis 30:1097-1105(2009)

PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164
Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H., Sekido Y.
LATS2 is a tumor suppressor gene of malignant mesothelioma.
Cancer Res. 71:873-883(2011)

PubMed=22286761; DOI=10.1038/onc.2012.5
Mizuno T., Murakami H., Fujii M., Ishiguro F., Tanaka I., Kondo Y., Akatsuka S., Toyokuni S., Yokoi K., Osada H., Sekido Y.
YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.
Oncogene 31:5117-5122(2012)

PubMed=26011428; DOI=10.1111/cas.12698
Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y., Yokoi K., Sekido Y.
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.
Cancer Sci. 106:990-999(2015)

PubMed=28553954; DOI=10.1038/onc.2017.147
Kato T., Sato T., Yokoi K., Sekido Y.
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in merlin-negative malignant mesothelioma cells.
Oncogene 36:5522-5531(2017)